Authors:
Fajar Wahyu Pribadi
1
;
Afifah
1
and
Catharina Widiartini
2
Affiliations:
1
Department of Pharmacology, Faculty of Medicine, Universitas Jenderal Soedirman, Purwokerto, Indonesia, Indonesia
;
2
Department of Anatomy, Faculty of Medicine, Universitas Jenderal Soedirman, Purwokerto, Indonesia
Keyword(s):
cost analysis, type 2 diabetes mellitus, INA-CBG's rates, monotherapy, effectiveness.
Abstract:
Type 2 Diabetes Mellitus (D.M.) is a metabolic syndrome characterized by hyperglycemia due to decreased
insulin sensitivity. High prevalence and long-term treatment to be burdened on the health economy indicate
that D.M. therapy must be cost-effective. The study aimed to know the cost analysis monotherapy of type 2
Diabetes Mellitus patients. Twenty-three patients without complications were given monotherapy and
followed six months from D.M.'s initial diagnostic in a descriptive study. Data was taken from medical
records, clinical pathology laboratory and finansial data between January 1, 2016, and June 30, 2018. The
cost analysis therapy was compared between monotherapy Insulin, Metformin, Glimepiride and Pioglitazone.
Of the 23 patients monotherapy of the study population, nine patients received Insuline; 8 patients received
Metformin; 3 patients received Glimepirid, and three patients received Pioglitazone. The analysis showed that
the total cost INA-CBG's rates Rp9.0189
million; Rp7.9648 million; Rp2.9609 million and Rp2.9633 million.
Effectiveness therapy rates 44.44%; 70.83%; 50% and 66.67%. CER Rp202925; Rp112444; Rp59218 and
Rp44449. As a conclusion, Pioglitazone is more cost-effective when compared to Insulin, Metformin and
Glimepiride. Our findings suggest it needed to assess the total costs effectiveness of therapy with more and
longer periods.
(More)